Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation

Cell Prolif. 2009 Dec;42(6):751-61. doi: 10.1111/j.1365-2184.2009.00646.x. Epub 2009 Sep 15.


Background: Currently the most frequently used method for umbilical cord blood separation in many hospitals across the UK and the rest of the world, where small-to-medium amounts of samples are processed, is Hetastarch, a mechanical, starch-based method, which causes red cell agglutination by rouleaux formation.

Aim: In this study, a novel method (Prepa-Cyte-CB), in comparison with Hetastarch as part of an FDA-approved clinical study, was evaluated.

Materials and methods: Validation of data included recovery of nucleated and CD34+ cells, red blood cell reduction, colony forming unit potential, flow cytometric analysis and sterility tests.

Results: PrepaCyte-CB, in comparison with Hetastarch offers fast, reliable separation with improved recovery of nucleated cells, 72.03% (+/-8.48 SD) compared to 58.09% (+/-20.06 SD), and CD34+ haematopoietic progenitor cells, 76% (+/-19.54 SD) compared to 64.19% (+/-29.77 SD). PrepaCyte-CB was also 12-fold more efficient in removing red blood cells and haemoglobin (P < 0.001) than Hetastarch.

Conclusions: These results show that PrepaCyte-CB offers superior separation of UCB when compared to Hetastarch.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies*
  • Antigens, CD34 / immunology
  • Cell Separation / methods*
  • Cryopreservation
  • Fetal Blood / cytology*
  • Flow Cytometry
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / immunology
  • Humans
  • Hydroxyethyl Starch Derivatives*


  • Antibodies
  • Antigens, CD34
  • Hydroxyethyl Starch Derivatives